WallStSmart

Regencell Bioscience Holdings Ltd (RGC)vsTakeda Pharmaceutical Co Ltd ADR (TAK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

TAK leads profitability with a 2.5% profit margin vs 0.0%. TAK earns a higher WallStSmart Score of 60/100 (C).

RGC

Avoid

20

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 2/9

TAK

Buy

60

out of 100

Grade: C

Growth: 4.7Profit: 4.5Value: 4.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for RGC.

TAKSignificantly Overvalued (-77.5%)

Margin of Safety

-77.5%

Fair Value

$10.30

Current Price

$18.29

$7.99 premium

UndervaluedFair: $10.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RGC1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

TAK4 strengths · Avg: 9.8/10
PEG RatioValuation
0.3910/10

Growing faster than its price suggests

Price/BookValuation
0.6x10/10

Reasonable price relative to book value

Free Cash FlowQuality
$317.47B10/10

Generating 317.5B in free cash flow

Market CapQuality
$56.99B9/10

Large-cap with strong market position

Areas to Watch

RGC4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

TAK4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
4.2%4/10

4.2% revenue growth

EPS GrowthGrowth
3.3%4/10

3.3% earnings growth

Return on EquityProfitability
1.5%3/10

ROE of 1.5% — below average capital efficiency

Profit MarginProfitability
2.5%3/10

2.5% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : RGC

The strongest argument for RGC centers on Debt/Equity.

Bull Case : TAK

The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.39 suggests the stock is reasonably priced for its growth.

Bear Case : RGC

The primary concerns for RGC are Revenue Growth, EPS Growth, Profit Margin.

Bear Case : TAK

The primary concerns for TAK are Revenue Growth, EPS Growth, Return on Equity. A P/E of 82.0x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.

Key Dynamics to Monitor

RGC carries more volatility with a beta of 2.07 — expect wider price swings.

TAK is growing revenue faster at 4.2% — sustainability is the question.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TAK scores higher overall (60/100 vs 20/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Regencell Bioscience Holdings Ltd

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Regal Entertainment Group, is a film exhibitor in the United States. The company is headquartered in Knoxville, Tennessee.

Visit Website →

Takeda Pharmaceutical Co Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?